FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

wasnington,	D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BARER SOL J						2. Issuer Name and Ticker or Trading Symbol NexImmune, Inc. [NEXI]									(Ch	eck all app X Direct	tor		10% Owner		ner
	(Fir	, INC.	Лidd	le)	3. Date of Earliest Transaction (Month/Day/Year) 03/18/2022										Office below	er (give t	itle		her (s low)	pecify	
9119 GA	ITHER RO	AD			4. If Amendment, Date							d (Month/E	ay/Yea		Individual or Joint/Group Filing (Check Applic Line)						plicable
(Street) GAITHERSBURG MD 20877																X Form	filed by	One Rep			
(City)	(Sta	ate) (Z	Zip)													reisc	<i>,</i> 11				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date		2. Transaction Date (Month/Day/Yea	Execution ar) if any		Execution Date,) if any		Date, Transac							5. Amount Securities Beneficiall Owned Following	Form:		Direct Indire Benef t (I) Owne		ficial ership		
								С	ode	v	An	nount	(A) or (D)	or Price		Reported Transactio (Instr. 3 an					
Common Stock 03/18/2			03/18/2022	2				P		3	0,000	A	A \$2.107 ⁽¹⁾		1,447,814(2)		D				
Common Stock															1,538,013		I		Held by B&S NexImmune Holdco LLC ⁽³⁾		
Common Stock														346,5	77	I		Helo Josh Bare	ua		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if a	Deemed scution Date, ny onth/Day/Year)		4. 5. Numb Transaction of Code (Instr. Derivativ				Expiration Date (Month/Day/Year) d					8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	. v	(A)	(D)	Date) Exercisa		ble	Expiration Date		Amour or Number of Title Shares							

Explanation of Responses:

- 1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.96 to \$2.28, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
- 2. Excludes 175,012 shares of common stock underlying options that are currently exercisable.
- 3. Mr. Sol Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein.
- 4. Mr. Sol Barer is the father of Joshua Barer. Mr. Sol Barer disclaims beneficial ownership of the securities held by Joshua Barer.

Remarks:

/s/ Andrew Pearce, Attorney-

03/21/2022

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.